ADVANCED DRUG DELIVERY REVIEWS

Vol. 30, Nos. 1–3 **CONTENTS** **2 March 1998**

Cited in: *Biological Abstracts; BIOSIS; Chemical Abstracts; CABS Office/Current Awareness in Biological Sciences; Current Contents/Life Sciences; Engineering Information, Inc.; Excerpta Medica (EMBASE); Maro Polymer Notes; Research Information Systems, Inc.*

Theme Title: NON-VIRAL GENE DELIVERY SYSTEMS

A. Rolland and P.L. Felgner (USA)
Preface 1

Introduction to Controllable Gene therapy

P. Lehn, S. Fabrega, N. Oudrhiri and J. Navarro (France)
Gene delivery systems: Bridging the gap between recombinant viruses and artificial vectors 5

C.R. Sclimenti and M.P. Calos (USA)
Assaying extrachromosomal gene therapy vectors that carry replication/persistence elements 13

S.S. Chua, Y. Wang, F.J. DeMayo, B.W. O'Malley and S.Y. Tsai (USA)
A novel RU486 inducible system for the activation and repression of genes 23

R.H. Durland and E.M. Eastman (USA)
Manufacturing and quality control of plasmid-based gene expression systems 33

Chemistry and Cellular Aspects

A.V. Kabanov and V.A. Kabanov (USA, Russian Federation)
Interpolyelectrolyte and block ionomer complexes for gene delivery: physicochemical aspects 49

S. Walker, M.J. Sofia and H.R. Axelrod (USA)
Chemistry and cellular aspects of cationic facial amphiphiles 61

A. Chonn and P.R. Cullis (Canada)
Recent advances in liposome technologies and their applications for systemic gene delivery 73

J.-S. Remy, B. Abdallah, M.A. Zanta, O. Boussif, J.-P. Behr and B. Demeneix (France)
Gene transfer with lipospermines and polyethylenimines 85

W. Zauner, M. Ogris and E. Wagner (Austria)
Polylysine-based transfection systems utilizing receptor-mediated delivery 97

L.C. Smith, J. Duguid, M.S. Wadhwa, M.J. Logan, C.-H. Tung, V. Edwards and J.T. Sparrow (USA)
Synthetic peptide-based DNA complexes for nonviral gene delivery 115

(continued on inside back cover)

0169-409X(19980302)30:1:3;1-4

5000

Submission of manuscripts: The **preferred** medium of final submission is on disk with accompanying manuscript (see "Electronic manuscripts" below).

Electronic manuscripts: Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs.

The preferred storage medium is a $5\frac{1}{4}$ or $3\frac{1}{2}$ inch disk in MS-DOS format, although other systems are welcome, e.g., NEC and Macintosh (in this case, save your file in the usual manner, do not use the option 'save in MS-DOS format'). Please **do not split** the article into separate files (title page as one file, text as another, etc.). Ensure that the letter 'l' and digit '1' (also letter 'O' and digit '0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your wordprocessor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter α). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your wordprocessor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the wordprocessor format. If your wordprocessor features the option to save files 'in flat ASCII", please do **not** use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and wordprocessing package used and label the disk with your name and the name of the file on the disk. After **final acceptance**, your disk plus one, final, printed and exactly matching version (as a printout) should be submitted together to the accepting editor. **It is important that the file on disk and the printout are identical.** Both will then be forwarded by the editor to Elsevier. Further information may be obtained from the Publisher.

Contributions should be sent to one of the Editors-in-Chief. The original manuscript plus three copies should be submitted so as to facilitate refereeing. A disk should be submitted at the point of final acceptance, together with an exactly matching printout.

Advanced Drug Delivery Reviews has no page charges

For a full and complete "Guide for Authors", please refer to
Advanced Drug Delivery Reviews, Vol. 27, No. 1, pages 95–96

All questions arising after acceptance of the manuscript, especially those relating to proofs, should be directed to Elsevier Science Ireland Ltd., Bay 15, Shannon Industrial Estate, Shannon, Co. Clare, Ireland, tel. 353 (61)471944; fax 353 (61)472144.

Publication information: Advanced Drug Delivery Reviews (ISSN 0169-409X). For 1998, Volumes 28–33 are scheduled for publication. Subscription prices are available upon request from the Publisher. Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by surface mail except to the following countries where Air delivery via SAL mail is ensured: Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, PR China, Singapore, South Africa, South Korea, Taiwan, Thailand, USA. For all other countries airmail rates are available upon request. Claims for missing issues should be made within six months of our publication (mailing) date.

(contents continued from outside back cover)

Preclinical and Clinical Studies

F.D. Ledley and T.S. Ledley (USA)
Pharmacokinetic considerations in somatic gene therapy 133
R.J. Mumper and A.P. Rolland (USA)
Plasmid delivery to muscle: Recent advances in polymer delivery systems 151
S.H. Cheng and R.K. Scheule (USA)
Airway delivery of cationic lipid: DNA complexes for cystic fibrosis 173
J.M. Isner (USA)
Arterial gene transfer of naked DNA for therapeutic angiogenesis: early clinical results 185
R.I. Grove and G.Y. Wu (USA)
Pre-clinical trials using hepatic gene delivery 199
D. Geddes and E. Alton (UK)
Cystic fibrosis clinical trials 205
M.-C. Hung, J.Y. Chang and X. Xing (USA)
Preclinical and clinical study of *HER-2/neu*-targeting cancer gene therapy 219

Printed in The United Kingdom